Mary Cunningham profile picture
Accepting New Patients
315 634-4112

Mary Cunningham, MD

CURRENT APPOINTMENTS

Division Chief of Gynecologic Oncology

SPECIALTIES

Gynecologic Oncology

LANGUAGES

English

PATIENT TYPE

Adults

CLINICAL TRIALS

GOG-3104-GS-US-682-6769 - A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Read more
NRG-GY036: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY
Read more
NRG-GY024: Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial
Read more
NRG-GY032 - A PHASE II STUDY OF TAILORED ADJUVANT THERAPY IN POLE-MUTATED AND p53- WILDTYPE/NSMP EARLY-STAGE ENDOMETRIAL CANCER (RAINBO BLUE & TAPER)
Read more
GOG-3086: REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
Read more
NRG-GY028: A PHASE IB AND RANDOMIZED PHASE II TRIAL OF MEGESTROL ACETATE WITH OR WITHOUT IPATASERTIB IN RECURRENT OR METASTATIC ENDOMETRIOID ENDOMETRIAL CANCER
Read more
EAY191-N5: A RANDOMIZED TRIAL OF NERATINIB, A PAN-ERBB INHIBITOR, ALONE OR IN COMBINATION WITH PALBOCICLIB, A CDK4/6 INHIBITOR, IN PATIENTS WITH HER2+ GYNECOLOGIC CANCERS AND OTHER SOLID TUMORS A ComboMATCH Treatment Trial
Read more
EAY191-N4: A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL. (ComboMATCH)
Read more
EAY191-Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Read more
NRG-GY026, A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma. (#NCT05256225)
Read more
NRG-CC008: A NON-RANDOMIZED PROSPECTIVE CLINICAL TRIAL COMPARING THE NON-INFERIORITY OF SALPINGECTOMY TO SALPINGO-OOPHORECTOMY TO REDUCE THE RISK OF OVARIAN CANCER AMONG BRCA1 CARRIERS [SOROCk]
Read more
NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Read more
A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer
Read more

DISEASES & CONDITIONS TREATED

Cervical Cancer
Endometrial Cancer/Uterine Cancer
Fallopian Tube Cancer
Ovarian Cancer
Vaginal Cancer
Vulvar Cancer

TREATMENTS / SERVICES

Gynecologic Laparoscopic Surgery

CLINICAL AFFILIATIONS

Madison-Irving Medical Center
475 Irving Avenue
Syracuse, NY 13210
315 634-4112

CLINICAL SECTION AFFILIATIONS

Obstetrics and Gynecology
Gynecologic Oncology
Upstate Cancer Center
Gynecologic Oncology
Women's Health Network
Obstetric, Gynecology & Urogynecology
Pelvic Health

CURRENT HOSPITAL PRIVILEGES

Upstate University Hospital
Crouse Hospital

CAMPUSES

Downtown